Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis

OBJECTIVE: Overall survival is the gold-standard outcome measure for phase 3 trials, but the need for a long follow-up period can delay the translation of potentially effective treatment to clinical practice. The validity of major pathological response (MPR) as a surrogate of survival for non small...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yujia, Qin, Jianjun, Wu, Yajing, Lin, Qiang, Wang, Jianing, Zhang, Wei, Liang, Fei, Hui, Zhouguang, Zhao, Min, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498860/
https://www.ncbi.nlm.nih.gov/pubmed/37247009
http://dx.doi.org/10.1097/JS9.0000000000000496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498860/
https://www.ncbi.nlm.nih.gov/pubmed/37247009
http://dx.doi.org/10.1097/JS9.0000000000000496

Ejemplares similares